Compare ESNT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | TECH |
|---|---|---|
| Founded | 2008 | 1976 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 9.2B |
| IPO Year | 2013 | 1989 |
| Metric | ESNT | TECH |
|---|---|---|
| Price | $65.23 | $58.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $68.00 | ★ $71.23 |
| AVG Volume (30 Days) | 640.5K | ★ 1.6M |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | ★ 1.91% | 0.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.87 | 0.49 |
| Revenue | ★ $1,263,558,000.00 | $1,216,732,000.00 |
| Revenue This Year | $3.87 | $2.33 |
| Revenue Next Year | $1.55 | $7.05 |
| P/E Ratio | ★ $9.46 | $120.82 |
| Revenue Growth | 2.04 | ★ 3.85 |
| 52 Week Low | $51.61 | $46.01 |
| 52 Week High | $67.09 | $79.28 |
| Indicator | ESNT | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 45.70 |
| Support Level | $65.41 | $58.54 |
| Resistance Level | $66.11 | $59.64 |
| Average True Range (ATR) | 0.89 | 1.45 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 46.29 | 49.84 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.